Pelthos Therapeutics PTHS Cash Flow Statement (2023-2026)

NYSE PTHS
$21.35 +0.43 (+2.08%)
As of: Sep 30, 2026 · 10:00 AM EDT
Reported Financials

Pelthos Therapeutics Quarterly Cash Flow Statement

Periods 14 quarters
Latest Jun 2026

Pelthos Therapeutics reported cash from operations of -$7.66M and free cash flow of -$7.67M for the quarter ended Jun 2026. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income -0.97M-0.95M-1.42M-4.04M-2.56M-1.77M-1.70M-1.93M-1.97M-3.45M-16.24M-21.66M-25.07M-23.42M
Depreciation and DepletionDep. & Depletion 0.07M0.66M0.47M0.28M
Share-based CompensationStock Comp. 0.27M0.33M0.34M0.79M0.29M0.46M0.52M0.53M0.49M0.41M2.76M1.80M1.91M2.76M
Deferred Taxes 7.85M
Asset Writedowns and ImpairmentWritedown 0.79M0.26M0.93M
Cash from OperationsCash from Ops. -0.17M-0.19M-0.26M-0.36M-1.99M-2.95M-0.18M-0.67M-0.63M-0.45M-15.26M-6.25M-13.13M-7.66M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles 0.68M0.88M1.03M1.04M
Depreciation & Amortization (CF)Dep. & Amort. 0.07M0.66M0.47M0.28M
Change in Working Capital
Change in ReceivablesChange Receivables 2.84M2.78M
Change in InventoryChange Inventory -0.16M-1.22M
Change in Account PayablesChange Payables 0.62M0.71M2.40M0.93M-2.67M3.16M-0.34M
Change in Accured ExpensesChange Accured Exp. 0.37M0.18M0.62M0.46M-0.15M-1.33M1.20M0.02M2.67M3.47M-1.91M8.31M
Other Working Capital ChangesOther WC Changes 0.22M-0.06M0.73M-0.03M-0.05M-0.00M1.46M-0.53M-0.50M0.07M
Investing Activities
Capital ExpendituresCapex 0.19M0.00M
Cash from Investing ActivitiesCash from Investing 2.76M-8.00M-0.19M-0.00M
Financing Activities
Other financing activitiesOther financing 1.81M
Cash from Financing ActivitiesCash from Financing 0.17M0.23M0.20M0.43M5.67M1.59M-0.97M-0.07M0.25M0.38M26.69M18.02M27.52M
Debt Issuance and Repayment
Non-Current Debt -0.21M-243.00243.00
Change in Capital Stock
Net Equity Issued and RepurchasedNet Equity Issued 5.97M0.12M
Additional items
Change in Cash -0.01M0.03M-0.06M0.07M3.67M-1.37M-1.15M-0.74M-0.38M-0.07M14.19M3.77M14.20M-7.67M
Free Cash FlowFCF -0.17M-0.19M-0.26M-0.36M-1.99M-2.95M-0.18M-0.67M-0.63M-0.45M-15.26M-6.25M-13.32M-7.67M
Net Cash FlowNCF -0.01M0.03M-0.06M0.07M3.67M-1.37M-1.15M-0.74M-0.38M-0.07M14.19M3.77M14.20M-7.67M

Pelthos Therapeutics Cash Flow Statement API

Pull Pelthos Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=PTHS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY